関連する実験動画
Updated: Feb 17, 2026

08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
7.7K
統合マルチオミクスは,クローン病を悪化させるビスフェノールAの分子メカニズムを解明する
Liangliang Dai1,2, Chenjie Qiu3
1Department of Urology, Wujin Hospital Affiliated With Jiangsu University, Changzhou, 213004, China, ujs.edu.cn.
Mediators of inflammation
|February 16, 2026
まとめ
ビスフェノールA (BPA) 曝露は,炎症と免疫反応に関与する重要な遺伝子に影響することによって,クローン病 (CD) を悪化させる可能性があります. この研究では,CDの5つのコア遺伝子と潜在的な治療標的を特定しました.
科学分野:
- 環境の健康 環境の健康
- 胃腸内科 胃腸内科
- 分子生物学は分子生物学である.
背景:
- ビスフェノールA (BPA) は,クローン病 (CD) の進行に関連した内分泌系を乱す化学物質です.
- BPAがCDに与える影響の正確な分子メカニズムは不明である.
研究 の 目的:
- BPAがCDを悪化させる方法を体系的に解明する.
- BPAの影響を受けたCDの主要なバイオマーカーと治療標的を特定する.
主な方法:
- BPA目標値とCDトランスクリプトミックのデータの統合分析.
- 機能的エンリッチメント,タンパク質-タンパク質相互作用 (PPI) ネットワーク,および機械学習分析により,コア遺伝子を特定します.
- 分子ドッキング,免疫浸透,および分子メカニズムを探求するための規制ネットワーク分析.
主要な成果:
- BPAとCDの65の重複遺伝子を特定し,炎症と免疫経路に富んだ.
- 診断の可能性のある5つのコア遺伝子 (HGF,IL1R1,MMP1,MMP2,NTRK2) をスクリーニングしました.
- BPAとコアタンパク質 (例えば,MMP2) との強い結合親和が確認され,免疫細胞と調節因子とのコア遺伝子をリンクしました.
結論:
- BPAは,炎症のバランス,細胞外マトリックスリモデリング,およびコア遺伝子を介して免疫ホメオスタシスを破壊することによって,CDを悪化させる可能性があります.
- HGF,IL1R1,MMP1,MMP2,およびNTRK2を,BPA誘発性CDの潜在的なバイオマーカーおよび治療標的として特定しました.
関連する概念動画
Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Chronic Bowel Disorders: Introduction
817
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
817
Irritable Bowel Syndrome I: Introduction
1.2K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
600
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
600

